Natixis’s PTC Therapeutics PTCT Stock Holding History

Natixis’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$8.05M	Buy	+124,240	New	+$9.05M	0.03%	387
2022 Q4	–	Sell	-25,000	Closed	-$1.26M	–	1301
2022 Q3	$1.26M	Buy	+25,000	New	+$1.22M	0.01%	710
2021 Q4	–	Sell	-113,000	Closed	-$4.2M	–	1324
2021 Q3	$4.2M	Sell	113,000 -97,892	-46%	-$4.02M	0.01%	583
2021 Q2	$8.91M	Hold	210,892	–	–	0.04%	296
2021 Q1	$10M	Buy	+210,892	New	+$12.5M	0.03%	376

Other funds holding PTCT

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

Natixis's PTCT Position: Q3 2026 in Review

Natixis opened a new position in PTC Therapeutics (PTCT) in Q3 2026: 124,240 shares worth $8.05M. The stake represents 0.03% of the portfolio and ranks #387 among its holdings. This is a return to the name: Natixis previously reported a position in PTCT as recently as Q3 2022.

Natixis first reported a position in PTCT in Q1 2021 and has held it in 5 quarters since. The position peaked at $10M in Q1 2021. 140 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.

Natixis held 124,240 shares of PTC Therapeutics worth $8.05M as of Q3 2026.
PTC Therapeutics was a new Natixis position in Q3 2026.
PTC Therapeutics made up 0.03% of Natixis's portfolio in Q3 2026, its #387 holding.
Natixis first reported a position in PTC Therapeutics in Q1 2021 and has held it in 5 quarters since.
Natixis's PTC Therapeutics position peaked at $10M in Q1 2021.
140 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.

Based on Natixis's 13F filing for Q3 2026, filed 6 Nov 2026.